Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) Director Robert Baltera purchased 50,000 shares of the company's stock in a transaction dated Tuesday, November 17th. The stock was purchased at an average price of $1.01 per share, for a total transaction of $50,500.00. Following the completion of...
Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) Director Robert Baltera purchased 50,000 shares of the company's stock in a transaction dated Tuesday, November 17th. The stock was purchased at an average price of $1.01 per share, for a total transaction of $50,500.00. Following the completion of...
Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Research analysts at Brookline Capital Markets cut their FY2026 earnings estimates for Palisade Bio in a note issued to investors on Wednesday, November 11th. Brookline Capital Markets analyst K. Raja now forecasts that the company will post earnings...
Palisade Bio received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for PALI-2108, an ulcerative colitis treatment.
Stock futures rise on Wednesday, with Verra Mobility's shares plunging 45% after Avis Budget Group terminated its agreement with the company. Other stocks moving lower in pre-market trading include Zscaler, Brain, LG Display, Zepp Health, Globalfoundries, Posco Holdings, Insulet, Palisade Bio...
Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) has received an average recommendation of 'Moderate Buy' from the eight analysts that are presently covering the firm, MarketBeat reports. One...
Palisade Bio (NASDAQ:PALI) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-palisade-bio-inc-stock...
As the market barrels into the final hour of trading, momentum is clustering around a powerful trio of themes, AI infrastructure, next-gen materials, and sustainable agriculture. $KBLB, $LOCL, $MRVL, $POET, $PALI, $FFAI
Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Investment analysts at Brookline Capital Markets issued their Q1 2026 earnings per share (EPS) estimates for Palisade Bio in a research note issued to...
Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Stock analysts at Brookline Capital Markets issued their Q3 2026 EPS estimates for Palisade Bio in a research report issued on Wednesday, April 15th. Brookline Capital Markets analyst K. Raja expects that the company will earn ($0.06) per share for th...